VTGN News and Press, VistaGen Therapeutics Inc. From 02/07/22

VistaGen (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders. The company has ann...

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depressi...

VistaGen (NASDAQ: VTGN) , a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that the company will participate ...

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxi...

VistaGen Therapeutics (NASDAQ: VTGN ), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders,...

VistaGen Therapeutics, Inc. (VTGN) Q2 2022 Earnings Conference Call November 10, 2021 5:00 PM ET Company Participants Mark Flather – Vice President of Investor Relations Shawn Singh – Chief Executive Officer Jerry Dotson – Chief Financial Officer Mark Smith – Chief...

VistaGen Therapeutics (NASDAQ:VTGN): Q2 GAAP EPS of -$0.07 misses by $0.01. Revenue of $0.36M (+9.1% Y/Y) beats by $0.1M. Press Release For further details see: VistaGen Therapeutics EPS misses by $0.01, beats on revenue

PALISADE Phase 3 clinical trials of PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) progressing on plan PH94B Phase 2A clinical program targeting additional potential anxiety indications launched in adjustment disorder with anxiety (...

OTCQX:ACRGF, ADMA, AEVA, DADAAMPE, AMWL, APP, APPH, ASND, ATO, OTCPK:ATUSF, AZUL, BANX, BARK, BIOL, BKEP, BMBL, BOXL, BRFS, BRKS, BROS, BSQR, BW, BYND, BZH, CBAY, CCCS, CCMP, CGRN, CLSD, CLVR, CRCT, CYCC, DARE, DGII, DIS, EDRY, EGLX, ELMS, ENS, EVOK, FICO, FIGS, FOSL, FSM, GAU, GDRX, GEVO, OT...

VistaGen Therapeutics (NASDAQ: VTGN ), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders,...